Engineering a multilayered micro-vascularized soft tissue graft: Integrating polyurethane composite nanofibres with co-cultures of human adipose-derived endothelial and stem cells.
Webb BCW., Tran G., Devaraj K., Lindsay E., Kuzmanov U., Gramolini AO.
Animal Study, published in Biomaterials (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biomaterials (2026)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41702229
- DOI
- 10.1016/j.biomaterials.2026.124064
Abstract (original English)
Soft tissue defects and injuries, such as gingival recession, those requiring dermal tissue filling, and other indications, affect millions worldwide, yet autologous grafting remains the standard of care in most instances, despite donor site morbidity and limited tissue availability. Tissue-engineered alternatives have strong potential to overcome these limitations. We evaluated an 8 mm-diameter, 1 mm-thick layered electrospun composite formed from polar/hydrophobic/ionic polyurethane with methacrylated gelatin (FD-PHI) and polycarbonate urethane (PCNU), seeded with a co-culture of human adipose-derived stem cells (ASCs) and microvascular endothelial cells (HAMVECs). A 1:2 HAMVEC:ASC ratio supported interconnected CD31 + network formation and upregulated key proangiogenic factors (e.g., artemin, IL-1β, CXCL16, Serpin B5, leptin) after 7 days in vitro. Constructs were implanted subcutaneously into immunocompromised rats. Both cellular and acellular layered grafts integrated with the host tissue, aided by interlayer spacing facilitating tissue infiltration; however, cellular constructs exhibited significantly greater vessel density and diameter at 90 days. Pro-angiogenic proteins such as TGFBI, ITGAV, THY1, and PARVA were upregulated at early timepoints, which subsided over time, suggesting that a temporary upregulation may be sufficient to induce long-term outcomes for vascular
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.